Aripiprazole
| Subclass of | heterocyclic compound |
|---|---|
| Get use | Medication |
| Stylized name | ARIPiprazole |
| Chemical formula | C₂₃H₂₇Cl₂N₃O₂ |
| Canonical SMILES | C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl |
| World Health Organisation international non-proprietary name | aripiprazole |
| Legal status (medicine) | boxed warning |
| Pregnancy category | Australian pregnancy category B3, US pregnancy category C |
| LiverTox likelihood score | LiverTox toxicity likelihood category E |
| Subject has role | antipsychotics, atypical antipsychotic |
Aripiprazole, dem sell under de brand name Abilify, Aripiprex, Ariply among odas, be an atypical antipsychotic[1] dem primarily use insyd de treatment of schizophrenia, bipolar disorder, den irritability dem associate plus autism spectrum disorder;[1] oda uses dey include as an add-on treatment for major depressive disorder den tic disorders.[1] Dem dey take aripiprazole by mouth anaa via injection into a muscle.[1]
Common side effects dey include restlessness, insomnia, transient weight gain, nausea, vomiting, constipation, dizziness, den mild sedation.[1] Serious side effects fi include neuroleptic malignant syndrome, tardive dyskinesia, den anaphylaxis.[1] E no be recommended give older people plus dementia-related psychosis secof an increased risk of death.[1] Insyd pregnancy, der be evidence of possible harm to de fetus.[1][2] E no be recommended insyd women wey be breastfeeding.[1] E no be very well studied insyd people younger dan 18 years old.[1]
Na dem approve aripiprazole for medical use insyd de United States insyd 2002.[1] E be available as a generic medication.[3] Insyd 2023, na e be de 95th most commonly prescribed medication insyd de United States, plus more dan 7 million prescriptions.[4][5] E be on de World Health Organization's List of Essential Medicines.[6]
References
[edit | edit source]- 1 2 3 4 5 6 7 8 9 10 11 "Aripiprazole (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 26 November 2020. Retrieved 26 February 2019.
- ↑ "Prescribing medicines in pregnancy database". tga.gov.au. Therapeutic Goods Administration, Government of Australia. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
- ↑ British national formulary: BNF 76 (76th ed.). Pharmaceutical Press. 2018. p. 392. ISBN 978-0-85711-338-2.
- ↑ "The Top 300 of 2023". clincalc.com. Archived from the original on 12 August 2025. Retrieved 13 August 2025.
- ↑ "Aripiprazole - Drug Usage Statistics, ClinCalc DrugStats Database". clincalc.com. Retrieved 13 August 2025.
- ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Read further
[edit | edit source]- Dean L (2016). "Aripiprazole Therapy and CYP2D6 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520375. Bookshelf ID: NBK385288. Archived from the original on 26 October 2020. Retrieved 7 February 2020.
External links
[edit | edit source]- "Mechanism of Action of Aripiprazole". Psychopharmacology Institute.
- Commons category link from Wikidata
- 2,3-Dichlorophenylpiperazines
- 5-HT2A agonists
- 5-HT2A antagonists
- 5-HT2B agonists
- 5-HT2B antagonists
- 5-HT2C agonists
- 5-HT2C antagonists
- 5-HT7 antagonists
- Alpha-1 blockers
- Alpha-2 blockers
- Antiaggressive drugs
- Antidepressants
- Atypical antipsychotics
- Drugs wey Bristol Myers Squibb develop
- D2 antagonists
- D2 receptor agonists
- D3 antagonists
- D3 receptor agonists
- Ethers
- H1 receptor antagonists
- Hallucinogen antidotes
- Mood stabilizers
- Otsuka Pharmaceutical
- Serotonin-dopamine activity modulators
- Tetrahydroquinolines
- Treatment of autism
- VMAT inhibitors
- Translated from MDWiki